Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Key words Protein farnesylation inhibitor  (1)
  • farnesyl-protein transferase  (1)
  • 1
    ISSN: 1432-0843
    Keywords: Key words Protein farnesylation inhibitor ; Human prostate tumors ; Efficacy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: These studies sought to evaluate the antitumor properties of an inhibitor of ras functionality, L-744,832, which acts at the level of its associated protein farnesyltransferase. Methods: Studies were carried out to measure the effects of L-744,832 alone and in combination with paclitaxel (PTXL) against TSU-PR1, DU-145 and PC-3 human prostate tumors xenografted to NCR-nu1 (AT) mice. Tumor-bearing mice were treated on a schedule of daily for 5 days ×2 or 3 with the MTD of L-744,832 and every 3–4 days ×4 with the MTD of PTXL starting 3–5 days after tumor implantation. Tumor volume in millimeters (4/3πr3) was measured 3–5 days after cessation of treatment and the increase in tumor volume in treated and control groups compared. Statistical analysis was carried out by the Chi-squared test. Results: L-744,832 at its MTD markedly inhibited the growth of all three tumors (T/C for increase in tumor mass varied from 11% to 15% and inhibition of growth had a rapid onset (within 1–2 days) and was independent of ras gene status. Estimated tumor doubling times were 8–12-fold greater in treated animals than in control animals. Treatment with L-744,832 for as long as 3 weeks had no untoward effects on the mice as determined by gross examination or necropsy. Administration of L-744,832 with this same dose and schedule potentiated the growth-inhibitory effect of PTXL at its MTD and induced some regression of TSU-PR1 with no obvious deleterious effects on the mice. Conclusions: L-744,832 could be safely administered over a protracted period of time to mice at doses which were markedly inhibitory to the growth of three human prostate tumor xenografts and in combination with PTXL was also well tolerated and brought about some regression of the TSU-PR1 tumor. Overall, these results suggest that L-744,832 could be clinically useful for long-term treatment of early-stage prostate cancer in patients and as an adjunct to cytotoxic therapy for late stages of this disease.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    New York, N.Y. : Wiley-Blackwell
    Journal of Cellular Biochemistry 59 (1995), S. 145-150 
    ISSN: 0730-2312
    Keywords: CAAX peptidomimetic ; farnesyl-protein transferase ; protein prenylation ; ras oncogene ; Life and Medical Sciences ; Cell & Developmental Biology
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Biology , Chemistry and Pharmacology , Medicine
    Notes: Protein prenylation, adding either the 15-carbon isoprenoid farnesy1 or the 20-carbon isoprenoid geranylgeranyl to cysteine residue(s) at or near the C-termini of proteins, is a recently identified post-translational modification that localizes some proteins to a membrane compartment. One of the most intensely studied prenylated proteins is Ras, a low molecular weight GTP-binding protein that plays an important role in the regulation of cell proliferation. Proteins encoded by ras genes with oncogenic mutations are capable of tranforming cells in culture. Such mutate ras genes are frequently found in a wide variety of human tumors. Localization of the Ras oncoprotein to the cytoplasmic face of the plasma membrane via farnesylation is essential for efficient cell transforming ability. Thus, inhibition of the Ras farnesylation reaction is a possible anti-cancer strategy.Several strategies have been employed to inhibit Ras farnesylation, including inhibition of isoprenoid biosynthesis and inhibition of the enzyme which catalyzes the farnesylation reaction, farnesyl-protein transferase (FPTase). Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme. A reductase, the rate limiting enzyme in isoprenoid biosynthesis, inhibit Ras farnesylation and block the growth of ras-transformed cells. However, antiproliferative effects do not result from speicific inhibition of Ras farnesylation; they are also observed in cells transformed by raf, which is independent of Ras farensylation. A more specific approach to inhibiting Ras farnesylation is to inhibit FPTase. Using randon screeing of natural products and a rational design approach, a variety of compounds that specifically inhibit FPTase have been isolated. Several of these compounds were found to block the farnesylation of Ras proteins in cell culture and were able to block the anchorage-independent growth of ras-transformed cells and human tumor cell lines. FPTase inhibitors also blocked the morphologic alteration associated with ras-induced transformation of mammalian cells. In contrast, these compounds did not affect the growth or morphology of cells transformed by the raf or mos oncogenes, which do not require farnesylation to achieve biological activity. Furthermore, these compounds suppressed the growth of tumors arising from ras-transformed cells in nude mice in the absence of systemic toxicity. Control tumors formed by raf- or mos- transformed cells were not affected by these compounds. These studies suggest that FPTase inhibitors might be safe and effective chemotherapeutic agents.
    Additional Material: 3 Ill.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...